

Press Release

11 October 2022 13:00:00 CEST

Swedish innovation help to accelerate diagnosis of leukemia for children

- Qlucore's software is used in leading research projects

Swedish Qlucore - a leader in precision diagnostics for the analysis of cancer - has played an important role in the Swedish-Danish collaboration iCOPE, which aims, among other things, to improve the treatment of children affected by acute leukemia. With diagnoses increasing by 6-10 percent a year in Europe, acute leukemia in children still experiences high mortality and treatment-related complications.

The iCOPE collaboration, which is financed by EU grants, has been operating for three years, and spans the Öresund region. It includes patients and researchers from Skåne region, Lund University, Rigshospitalet and the Technical University of Denmark.

"Here, our proprietary software is very useful, both during the project and now also as a permanent solution. It enables easier assessment of a cancer's subgroup by analyzing large amounts of data. This is something that can be labor-intensive and cumbersome with traditional methods," says Carl-Johan Ivarsson, Qlucore's CEO.

With the help of the Qlucore Insights software, iCOPE aims to improve the so-called precision diagnostics in acute leukemia.

"We chose Qlucore's software because it is automated, user-friendly and has a perfect visual presentation - almost like 3D. This is good for doctors with limited understanding of childhood leukemia, as well as parents as it is easy to print a result and show them," says Kjeld Schmiegelow (Professor and Senior Hospital Physician).

With the help of precision diagnostics based on so-called RNA sequencing, iCOPE can improve care for children affected by acute childhood leukemia.

"The best thing is that we can implement RNA sequencing in clinical diagnostics in a simple and safe way and that the software helps us in this important work. If we hadn't had access to Qlucore's software, it would have required a lot of work by specialized bioinformaticians, researchers and doctors, which would have been both costly and time-consuming," says Mette Klarskov Andersen, doctor at Rikshospitalet in Copenhagen.

She continues: "We have had many software solutions presented to us in the past, but none of these have met our desires or been designed to suit our needs. This software has impressed us and makes it possible to design the right treatment method and eventually move towards personalized care and medication".

Certified Advisor

FNCA Sweden AB
Web: www.fnca.se

Contacts

Press contact:
Chaz Brooks / Alison Scarrott / Mandy Brooks
Brookscomm
Phone: +44 (0) 1483 537 890
Email: alison@brookscmm.com

QluCore contact:
Carl-Johan Ivarsson, CEO
Phone: +46 (0) 46 286 31 14
Email: carl-johan.ivarsson@qlucore.com

About QluCore

QluCore is a leading provider of new generation intuitive bioinformatics software for research and precision and companion diagnostics. QluCore's mission is to make it easier to analyze the huge amounts of complex data generated by innovations in the fields of genomics and proteomics by providing powerful visualization-based bioinformatics data analysis tools for research and precision diagnostics. QluCore Omics Explorer software is a Do-It-Yourself bioinformatics software for research in the life science, plant- and biotech industries, as well as academia. QluCore Diagnostics and QluCore Insights are software platforms with built in AI-based machine learning for multi-omics companion and precision diagnostics. QluCore was founded in 2007 in Lund, Sweden and has customers in about 25 countries around the world, with sales offices in Europe and North America, and distribution in several countries in Asia. QluCore is listed on the Nasdaq First North Growth market. www.qlucore.com

Attachments

[Swedish innovation help to accelerate diagnosis of leukemia for children](#)